Verona Pharma

Acquired

Innovative Respiratory Treatments

Headquarters
London
Employees
51–200
Business Model
B2B

About

Verona Pharma was a clinical-stage biopharmaceutical company headquartered in London, UK, with US offices in Raleigh, NC and Savannah, GA, focused on developing and commercializing novel treatments for chronic respiratory diseases including COPD, asthma, and cystic fibrosis. The company's lead product, Ohtuvayre (ensifentrine), became the first inhaled therapy for COPD maintenance treatment combining bronchodilator and non-steroidal anti-inflammatory activities in a single molecule. Verona Pharma was acquired by Merck in 2025 for approximately $10 billion.

Summary

Verona Pharma is a Biotech company based in London, United Kingdom. Investors include Oaktree Capital Management, RA Capital Management and OMERS Life Sciences.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Debt FinancingDebt FinancingMay 2024
$650.0M

Sign up to see all 4 rounds

IPO through Debt Financing — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Verona Pharma on Indexed.vc
<a href="https://indexed.vc/companies/verona-pharma"><img src="https://indexed.vc/api/badge/company/verona-pharma" alt="Verona Pharma on Indexed.vc" width="260" height="76" /></a>